[Summery]  he first target is tau protein, which is known to influence the development of several degenerative brain diseases, including frontal dementia and Alzheimer's disease. PeopleBio and Absolology will first begin developing a blood-based diagnostic kit that measures tau protein, an important factor in Alzheimer's disease. It also plans to jointly develop upgraded products in the beta amyloid field.

https://www.fnnews.com/news/202106181628487135

Excerpt from Financial News